Drug Trial Radar · NCT03511664
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
861
Actual
Start
May 29, 2018
Primary completion
Jan 27, 2021
Study completion Dec 14, 2023
Sponsor
- Lead sponsor
- EndocyteIndustry
- Sponsor type
- Industry
- First posted
- Apr 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.
Conditions
- Prostate Cancer
Interventions
177Lu-PSMA-617Drug
Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
Best supportive/best standard of careOther
Best supportive/best standard of care as defined by the local investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-free Survival (rPFS)Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 32 months (Primary Analysis cut-off date = 27-Jan-2021)
- Overall Survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to 32 months (Primary Analysis cut-off date = 27-Jan-2021) and up to 66 months (Final Analysis cut-off date = 14-Dec-2023)
Locations
88 sites in 10 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
University of Arizona Cancer Center
Tucson, Arizona
VA Greater Los Angeles Healthcare System
Los Angeles, California
University of California Los Angeles, Nuclear Medicine
Los Angeles, California
Stanford Cancer Institute
Palo Alto, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
University of Colorado Hospital
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Washington DC VA Medical Center, Nuclear Medicine Service
Washington D.C., District of Columbia
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Northwestern University
Chicago, Illinois
Parkview Research Center
Fort Wayne, Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Iowa City VA Medical Center
Iowa City, Iowa
Norton Cancer Institute
Louisville, Kentucky
Tulane Medical Center, Tulane Cancer Center
New Orleans, Louisiana
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Chesapeake Urology Associates (CUA) P.A.
Towson, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
VA Ann Arbor Healthcare System
Ann Arbor, Michigan
University of Michigan Hospitals
Ann Arbor, Michigan
Karmanos Cancer Center
Detroit, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
Saint Louis University Hospital
St Louis, Missouri
VA St. Louis Health Care System - John Cochran
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
XCancer Omaha / Urology Cancer Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada - Twain Office
Las Vegas, Nevada
Regional Cancer Care Associates, Central Jersey Division
East Brunswick, New Jersey
New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center
Albuquerque, New Mexico
Memorial Sloan Kettering Cancer Center
New York, New York
New York Presbyterian Hospital/Weill Cornell Medical Center
New York, New York
Duke University Medical Center, Duke Cancer Center
Durham, North Carolina
Greater Dayton Cancer Center
Kettering, Ohio
Oregon Health and Science University, Nuclear Medicine
Portland, Oregon
Pennsylvania Cancer Specialists & Research Institute
Gettysburg, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.